Last reviewed · How we verify

Clopidogrel (Iscover/Plavix) — Competitive Intelligence Brief

Clopidogrel (Iscover/Plavix) (Clopidogrel (Iscover/Plavix)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P2Y12 receptor antagonist / Thienopyridine antiplatelet agent. Area: Cardiovascular.

phase 3 P2Y12 receptor antagonist / Thienopyridine antiplatelet agent P2Y12 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Clopidogrel (Iscover/Plavix) (Clopidogrel (Iscover/Plavix)) — Stiftung Institut fuer Herzinfarktforschung. Clopidogrel irreversibly inhibits platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor on platelets.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Clopidogrel (Iscover/Plavix) TARGET Clopidogrel (Iscover/Plavix) Stiftung Institut fuer Herzinfarktforschung phase 3 P2Y12 receptor antagonist / Thienopyridine antiplatelet agent P2Y12 receptor
Dabigatran + clopidogrel Dabigatran + clopidogrel Zuyderland Medisch Centrum marketed Anticoagulant + antiplatelet agent combination Thrombin (Factor IIa) and P2Y12 receptor
clopidogrel bisulfate + aspirin clopidogrel bisulfate + aspirin Seoul National University Hospital marketed Dual antiplatelet agent P2Y12 receptor (clopidogrel); cyclooxygenase (aspirin)
bivalirudin + clopidogrel + aspirin bivalirudin + clopidogrel + aspirin Centre Hospitalier de PAU marketed Anticoagulant + antiplatelet combination Thrombin (Factor IIa), P2Y12 receptor, cyclooxygenase
Clopidogrel active metabolite Clopidogrel active metabolite University of Florida marketed P2Y12 receptor antagonist / Antiplatelet agent P2Y12 receptor
ASA plus Clopidogrel ASA plus Clopidogrel Texas Cardiac Arrhythmia Research Foundation marketed Dual antiplatelet agent COX-1 (aspirin); P2Y12 receptor (clopidogrel)
Switch ticagrelor to clopidogrel Switch ticagrelor to clopidogrel The First Affiliated Hospital with Nanjing Medical University marketed P2Y12 receptor antagonist; antiplatelet agent P2Y12 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (P2Y12 receptor antagonist / Thienopyridine antiplatelet agent class)

  1. Azienda Policlinico Umberto I · 1 drug in this class
  2. Hospital Central San Luis Potosi, Mexico · 1 drug in this class
  3. Sanofi · 1 drug in this class
  4. Seung-Jung Park · 1 drug in this class
  5. Stiftung Institut fuer Herzinfarktforschung · 1 drug in this class
  6. US Department of Veterans Affairs · 1 drug in this class
  7. University of Pecs · 1 drug in this class
  8. VA Office of Research and Development · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Clopidogrel (Iscover/Plavix) — Competitive Intelligence Brief. https://druglandscape.com/ci/clopidogrel-iscover-plavix. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: